GKOS logo

GLAUKOS CORP

GKOSNYSE
🏆 #922 by market capEarnings Nov 4US Equity
$158.42▼ $0.43 (−0.27%)
Market closed · at close
🔔
Track GKOS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.3%
7d▲ 3.2%
14d▼ 2.8%
30d▼ 11.8%
ytd▲ 40.4%
1y▲ 94.1%
🏦Market Cap
$9.34B
Small Cap
📈Revenue Growth (YoY)
+32.3%
High Growth
📊Gross Margin
79.1%
High
💵FCF Margin
-2.0%
Thin
⚖️P/S Ratio
15.3x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$156.42 – $161.54
52-Week Range
$73.16 – $191.62
Volume
$2.82B
Avg Volume
$3.18B
Shares Outstanding
59.0M
Next Earnings
Nov 30, 2026

Fundamentals Snapshot

Annual Revenue
$507M
Last Q Revenue
$186M
P/E Ratio
-48.8
P/S Ratio
15.3x
EPS (TTM)
$-3.22
Dividend Yield
0.00%
Dilution (1yr)
+3.5%

Why Investors Own GKOS

  • ✓High-growth profile — revenue up +9.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GKOS logo

GLAUKOS CORP

GKOS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$507M▲ +32.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.5%▲ +2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$87M▼ −29.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$54M▼ −20.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
57.5M▲ +3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$49M▼ −$115M YoY
StockOtter · stockotter.space

About GLAUKOS CORP

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$209.27
▲ +32.1% Upside
High Target$226.43
Low Target$177.19
Based on 36 analysts

Latest News & Updates

🚀
Reuters·2h ago

GLAUKOS CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift GKOS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

GLAUKOS CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.